Open Access. Powered by Scholars. Published by Universities.®
- Keyword
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Lac+ Saccharomyces Cerevisiae, Robert C. Dickson, Kotikanyadanam K. Sreekrishna
Lac+ Saccharomyces Cerevisiae, Robert C. Dickson, Kotikanyadanam K. Sreekrishna
Molecular and Cellular Biochemistry Faculty Patents
The invention relates to novel, transformed strains of Lac+ Saccharomyces cerevisiae, capable of utilizing lactose as a sole carbon source, produced by inserting into the Saccharomyces cerevisiae a plasmid containing a lactose permease and a beta-galactosidase gene derived from Kluyveromyces lactis yeast.
Phenylbutyl Nitrone Compositions And Methods For Prevention Of Gastric Ulceration, Robert A. Floyd, John M. Carney
Phenylbutyl Nitrone Compositions And Methods For Prevention Of Gastric Ulceration, Robert A. Floyd, John M. Carney
Pharmacology and Nutritional Sciences Faculty Patents
Compositions containing PBN, or active derivatives thereof, in a suitable pharmaceutical carrier for administration to a patient, are disclosed for treating or preventing gastric ulceration caused by ingestion of non-steroidal anti-inflammatories. Based on animal studies, the dosage is in the range of 3 to 300 mg/kg and is administered prior to, simultaneously, or shortly after ingestion of the NSAID compound(s). In the preferred embodiment, the range is between 10 and 30 mg/kg, depending on the dosage unit required to protect the mucosa. The preferred method of administration is orally, alone or in combination with the non-steroidal anti-inflammatory. It is believed …
Phenyl Butyl Nitrone Compositions And Methods For Treatment Of Oxidative Tissue Damage, John M. Carney, Robert A. Floyd
Phenyl Butyl Nitrone Compositions And Methods For Treatment Of Oxidative Tissue Damage, John M. Carney, Robert A. Floyd
Pharmacology and Nutritional Sciences Faculty Patents
Compositions for treating tissue damage from ischemia contain PBN, or active derivatives thereof, which are active during ischemia in preventing ATP depletion of the cells which predisposes them to subsequent injury during reperfusion, and which are active during reperfusion as oxygen radical scavengers, in a suitable pharmaceutical carrier for systemic or local administration, especially to the CNS, spinal column and eyes. Based on animal studies, the dosage for treating damage due to stroke is in the range of 10 to 300 mg/kg. Similar dosages are useful in treating damage resulting from free radical generation during inflammation, either as a product …